Fig. 6.

The effect of PtPz4, PtPz6, cisPt, and anti-MUC1 on anti-apoptotic Bcl-xL mRNA (A), Bcl-xL protein (B), and Bcl-2 mRNA (C) expressions in DLD-1 and HT-29 colon cancer cells. The cells were incubated for 24 h with PtPz4 (10 μM), PtPz6 (10 μM), cisPt (10 μM), anti-MUC1 (5 μg/mL), PtPz4 + anti-MUC1 (10 μM + 5 μg/mL), PtPz6 + anti-MUC1 (10 μM + 5 μg/mL), and cisPt + anti-MUC1 (10 μM + 5 μg/mL). mRNAs were determined by RT-PCR. The results are presented as a relative fold change in mRNA expression of gene in comparison of gene in control where expression was set as 1. ±SD are the mean of triplicate cultures. *P < 0.05, **P < 0.01, ***P < 0.001 compared to untreated control; ^##P < 0.01, ^###P < 0.001 compared to PtPz4 monotherapy; ^ΔΔP < 0.01, ^ΔΔΔP < 0.001 compared to PtPz6 monotherapy; ^††P < 0.01, ^†††P < 0.001 compared to cisPt monotherapy; ^‡P < 0.05, ^‡‡‡P < 0.001 compared to anti-MUC1 monotherapy. Bcl-xL protein expression in cell lysates was assessed by Western blotting. The intensities of the bands were quantified by densitometric analysis. Data show the mean ±SD of the relative expression levels (from 3 assays) standardized to β-actin. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the untreated control; ^###P < 0.001 compared to PtPz4 monotherapy; ^ΔP < 0.05 compared to PtPz6 monotherapy; ^†††P < 0.001 compared to cisPt monotherapy; ^‡‡P < 0.01 compared to anti-MUC1 monotherapy.